I have long planned to write my opinion on Cellceutix (OTCQB:CTIX), which I consider one of the most exciting oncology-focused biotech companies. Despite the usual risks of an early-stage biotech, I find their p53 activator compound Kevetrin one of the most interesting things to follow.
However, when Cellceutix acquired PolyMedix assets from bankruptcy in September 2013, I was not sure what to make out of it. A biotech company developing cancer drugs is buying an antibiotic company's assets? I must admit that my impression was not positive at first. I prefer when an early-stage biotech company stays focused on the key compounds. After some time, I analyzed the acquisition in more depth and started developing a sneaking suspicion...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|